文献速递艾滋病与性传播感染

ACTG A5353:多替拉韦联合拉米夫定初始治疗HIV-1的试点研究

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.
PubMed 文献 · Clin Infect Dis · 2018-01-01

A5353是一项2期单臂试点研究,评估多替拉韦(50 mg)联合拉米夫定(300 mg)每日一次初始治疗HIV-1 RNA≥1000且<500000 copies/mL的初治感染者。120名参与者中,第24周HIV-1 RNA<50 copies/mL的比例为90%(95%CI 83%-95%),但1例发生M184V和R263R/K耐药突变。

要点

  • 多替拉韦联合拉米夫定在HIV-1 RNA<500000 copies/mL初治者中第24周病毒学抑制率达90%。
  • 病毒学失败者中1例出现M184V和R263R/K耐药突变,需警惕耐药风险。
  • 研究排除活动性乙肝和主要耐药突变者,结果不能外推至这些人群。

核心结论

  • 多替拉韦联合拉米夫定在基线HIV-1 RNA<500000 copies/mL的初治感染者中显示有效,但1例发生耐药突变。

研究设计与样本

  • A5353为2期单臂试点研究,纳入120例初治HIV-1感染者,接受多替拉韦50 mg联合拉米夫定300 mg每日一次。
  • 纳入标准为HIV-1 RNA≥1000且<500000 copies/mL;排除活动性乙肝及主要蛋白酶、逆转录酶或整合酶耐药。

主要发现

  • 第24周HIV-1 RNA<50 copies/mL(FDA Snapshot)比例为108/120(90%,95%CI 83%-95%)。
  • 基线HIV-1 RNA>100000 copies/mL亚组病毒学抑制率为89%(95%CI 75%-97%),≤100000 copies/mL亚组为90%(95%CI 82%-96%)。
  • 3例病毒学失败者中至少1个时间点血浆多替拉韦未检出,1例出现M184V和R263R/K突变。
  • 2例发生3级可能/很可能与治疗相关的不良事件,无因不良事件停药。

关键数值与推荐

  • 病毒学失败定义为第16/20周确认HIV-1 RNA>400 copies/mL或第24周及以后>200 copies/mL。
  • 基线中位HIV-1 RNA为4.61 log10 copies/mL,中位CD4计数为387 cells/mm3。

临床怎么用

  • 对于基线HIV-1 RNA<500000 copies/mL且无活动性乙肝及主要耐药的初治者,可考虑多替拉韦联合拉米夫定方案,但需监测病毒学反应和耐药。

局限性

  • 单臂试点研究,样本量120例,无对照臂,结论需更大规模随机试验验证。
  • 排除活动性乙肝和主要耐药突变者,结果不能推广至这些人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment with dolutegravir plus lamivudine. METHODS: A5353 is a phase 2, single-arm, pilot study of once-daily dolutegravir (50 mg) plus lamivudine (300 mg) in treatment-naive participants with HIV-1 RNA ≥1000 and <500000 copies/mL. Exclusion criteria included active hepatitis B or major protease, reverse transcriptase, or integrase resistance. The primary efficacy measure was the proportion with HIV-1 RNA <50 copies/mL (FDA [US Food and Drug Administration] Snapshot) at week 24. Virologic failure (VF) was confirmed HIV-1 RNA >400 copies/mL at week 16/20 or >200 copies/mL at or after week 24. Dolutegravir levels and drug resistance testing were performed at VF. RESULTS: One hundred and twenty participants (87% male, median age 30 years, 37 (31%) HIV-1 RNA >100000 copies/mL) initiated study treatment. Median entry HIV-1 RNA and CD4 count were 4.61 log10 copies/mL and 387 cells/mm3. Virologic efficacy at week 24 was 108/120 (90%, confidence interval [83%, 95%]), with comparable results in the >100000 copies/mL and ≤100000 copies/mL strata, that is, 89% (75%, 97%) and 90% (82%, 96%), respectively. Three participants with VF, had undetected plasma dolutegravir at ≥1 time points; the M184V and R263R/K mutations developed in 1 participant. Two participants experienced grade 3 possible/probable treatment-related adverse events; none discontinued treatment due to adverse events. CONCLUSIONS: Dolutegravir plus lamivudine demonstrated efficacy in individuals with pretreatment HIV-1 RNA up to 500000 copies/mL in this pilot trial, but a participant developed resistance mutations. CLINICAL TRIALS REGISTRATION: NCT02582684.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Taiwo BO, Zheng L, Stefanescu A, et al. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis. 2018. PMID: 29253097. doi:10.1093/cid/cix1083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。